Cardiovascular Outcomes of Semaglutide in Adults With Congenital Heart Disease.
Listen to this summary
This retrospective TriNetX cohort study asked whether semaglutide, compared with DPP-4 inhibitors, is associated with better outcomes in adults with congenital heart disease and type 2 diabetes, a population excluded from cardiovascular outcome trials. In 1,422 propensity-matched pairs followed for 3 years, semaglutide was associated with lower all-cause mortality (HR 0.66), hospitalization (HR 0.68), and ED visits (HR 0.85), along with lower MACE, heart failure, and stroke, though a prespecified negative control was elevated, suggesting residual confounding from differences in healthcare engagement. The authors conclude the findings are hypothesis-generating only, given the observational design and imbalances such as more aortic valve disease among semaglutide users.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from The American journal of cardiology
View all →Nov 19, 2026 · The American journal of cardiology
Longitudinal NT-proBNP Target Attainment and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction: A Landmark Analysis of the GUIDE-IT Trial.
Nov 19, 2026 · The American journal of cardiology
Eximer Laser Coronary Atherectomy in the Current era of Complex Percutenoues Coronary Intervention: New Insights from the ACCELERATE (eAst siCily exCimEr LasER ATherEctomy) Registry.
Nov 19, 2026 · The American journal of cardiology
Timing of Coronary Angiography After Successful Fibrinolysis and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction Patients.
Nov 18, 2026 · The American journal of cardiology
Effect of High-Intensity Statin Therapy on Coronary Plaque Composition Assessed by Machine Learning-Based Optical Coherence Tomography Analysis.
Nov 18, 2026 · The American journal of cardiology
Differential Reverse Remodeling but Preserved Clinical Benefit of Sacubitril/Valsartan in Ischemic vs Non‑Ischemic HFrEF.
Nov 18, 2026 · The American journal of cardiology
Artificial Intelligence and Cardiovascular Disease Prevention: Newton's Second Law Readdressed with a Cautionary Note.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


